A sign hangs near the section for children's medicine at a Walgreens in New York City on Dec.19, 2022. (Photo by Fatih Aktas/Anadolu Agency via Getty Images)
Walgreens has ended limits it had imposed recently for online purchases of children’s over-the-counter fever reducing products.
The drugstore chain said improved supplies allowed it to lift its restriction of six products. The company had placed no limit on in-store purchases.
Last month both Walgreens and CVS Health restricted purchases of some over-the-counter children’s medicines citing supply issues. CVS Health put a two-product limit on all children’s pain relief products bought through its pharmacies or online.
A CVS Health spokeswoman said Tuesday that limits on some children's medicines remain in place. She did not offer a time frame for when it might end.
An unusually fast start to the annual U.S. flu season, plus a spike in other respiratory illnesses, created a surge in demand for fever relievers and other products people can buy without a prescription.
Shortages of medicines like Children’s Tylenol developed, varying around the country and sometimes even within communities.
Experts who track medicine shortages said in December that the problem could persist through the winter cold-and-flu season. But they noted that it should not last as long as other recent shortages of baby formula or prescription drugs.
Abigail Buckwalter, President and CEO of Ocean Spray, discusses its “Bog Core” fashion collection, reaching Gen Z and reinventing an iconic cranberry brand.
Chris Yu, founder and president of ALSO, explains how the Rivian spin-off is reinventing electric bikes and developing new solutions for urban delivery.
Irene Solaiman, Hugging Face's Chief Policy Officer and SVP of Strategy, discusses open-source AI, model sharing, safety and the fight for transparency.
Jack Withinshaw, CCO and co-founder of Airspeeder, explains how electric flying car racing could revolutionize motorsport and the future of transportation.
TIME reveals its 2026 Best Inventions list of 300 breakthroughs, featuring Apple CEO John Ternus and the iPhone Duo as he shares his vision for the future.
Seth Goldstein, Senior Equity Analyst at Morningstar, examines Tesla’s new Roadster, SpaceX merger speculation and the race to make robotaxis profitable.